🇺🇸 FDA
Pipeline program

FX006 32 mg

FX006-2014-007

Phase 2 small_molecule terminated

Quick answer

FX006 32 mg for Post-traumatic Osteoarthritis of the Knee is a Phase 2 program (small_molecule) at Pacira BioSciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Pacira BioSciences
Indication
Post-traumatic Osteoarthritis of the Knee
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials